Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28259608

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Apr
First author
Ladenstein R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Apr;18(4):423-424. doi: 10.1016/S1470-2045(17)30069-4.
    note
    Source null
    related pmid
    28259607
    relationship
    Comment in

Authors and identifiers

  1. name
    Ladenstein R
    type
    Author
  2. name
    Pötschger U
    type
    Author
  3. name
    Pearson ADJ
    type
    Author
  4. name
    Brock P
    type
    Author
  5. name
    Luksch R
    type
    Author
  6. name
    Castel V
    type
    Author
  7. name
    Yaniv I
    type
    Author
  8. name
    Papadakis V
    type
    Author
  9. name
    Laureys G
    type
    Author
  10. name
    Malis J
    type
    Author
  11. name
    Balwierz W
    type
    Author
  12. name
    Ruud E
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ladenstein R
    type
    Author
  2. name
    Pötschger U
    type
    Author
  3. name
    Pearson ADJ
    type
    Author
  4. name
    Brock P
    type
    Author
  5. name
    Luksch R
    type
    Author
  6. name
    Castel V
    type
    Author
  7. name
    Yaniv I
    type
    Author
  8. name
    Papadakis V
    type
    Author
  9. name
    Laureys G
    type
    Author
  10. name
    Malis J
    type
    Author
  11. name
    Balwierz W
    type
    Author
  12. name
    Ruud E
    type
    Author
bibliography ids
  1. nci-bib-1f97a87d2782b6bbf03aff6b
book metadata
content sha256
53e06446f340dbc4045ba068a87a8abdee2bd083ee78724947d2327f05657624
document type
citation
dois
  1. 10.1016/S1470-2045(17)30070-0
electronic publication date
display
2017 Mar 2
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28259608
immutable id
pubmed:28259608@53e06446f340dbc4045ba068a87a8abdee2bd083ee78724947d2327f05657624
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
500-514
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Apr;18(4):423-424. doi: 10.1016/S1470-2045(17)30069-4.
    note
    Source null
    related pmid
    28259607
    relationship
    Comment in
outcomes validated
false
pmid
28259608
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
88118ec813c7175e1b1bfca8622c654858eda1c1fd4435ec80ec237876258e80
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Apr
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28259608/
title
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Preserved source evidence · Not medical advice